Oragenics (OGEN) AI Stock Analysis

• Market Cap: $4.02M
• Dividend Yield: N/A
• Average Volume (3M): 363.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: -100.00%
• EPS Growth: 76.55%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 65
• Industry: Biotechnology
• EPS (TTM): -1.85
• Shares Outstanding: 21,475,288
• 10 Day Avg. Volume: 261,169
• 30 Day Avg. Volume: 363,157
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 148.29
• Price to Cash Flow (P/CF): -0.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Oragenics exhibits significant financial distress, with ongoing unprofitability, negative equity, and cash flow issues, contributing to a low financial performance score. The technical indicators reflect a weak stock momentum, further exacerbating the negative outlook. Valuation metrics are unfavorable due to negative earnings and lack of dividends, highlighting the challenges facing the company. Overall, the stock's fundamental and technical weaknesses are significant, resulting in a low overall score.

Oragenics Business Overview & Revenue Model

Company Description

Oragenics, Inc. (OGEN) is a biopharmaceutical company focused on the development of novel antibiotics and treatments for infectious diseases. The company operates primarily in the biotechnology sector, with a core emphasis on addressing antibiotic resistance and unmet medical needs through its research and development efforts. Oragenics is known for its proprietary lantibiotic platform, which is designed to create new antibiotics with unique mechanisms of action.

How the Company Makes Money

Oragenics generates revenue primarily through research and development collaborations, grants, and potential milestone payments from strategic partnerships. The company focuses on advancing its product candidates through various stages of clinical trials, aiming to out-license or co-develop these products with larger pharmaceutical companies. Revenue is also derived from government and private funding initiatives that support the development of new antibiotics and treatments for infectious diseases. Long-term, Oragenics aims to commercialize its proprietary products, thereby generating revenue through product sales and royalties.

Oragenics Financial Statement Overview

Summary

Oragenics is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The company's financial position is fragile, with minimal revenues and ongoing reliance on financing activities to sustain operations.

Income Statement

The company has experienced declining revenues over the years, with no revenues in 2024 and minimal revenues in previous years. Gross profit margins are negative, indicating cost inefficiencies or low sales volumes. The company has consistently reported negative EBIT and net income, reflecting ongoing unprofitability.

Balance Sheet

The balance sheet shows a negative stockholders' equity in 2024, indicating potential financial distress. The debt-to-equity ratio is not meaningful due to negative equity, though total liabilities have decreased over time. The company has maintained a high cash balance, which provides some liquidity despite ongoing losses.

Cash Flow

Operating cash flow has been negative, reflecting cash outflows from operations, though financing activities have provided some cash inflows. Free cash flow is consistently negative, which underscores the challenges in generating sufficient cash to cover operating and potential capital expenditures.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
-37.65K	0.00	37.65K	131.52K	86.99K	0.00
	Gross Profit
-12.65M	0.00	-15.45M	86.85K	45.75K	-51.70K
	EBIT
-9.73M	-10.56M	-20.90M	-14.42M	-15.77M	-26.64M
	EBITDA
-20.14M	-10.56M	-20.88M	-14.23M	-15.65M	-26.37M
	Net Income Common Stockholders
-19.97M	-10.57M	-20.66M	-14.16M	-15.73M	-26.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.21M	864.84K	3.48M	11.43M	27.27M	17.64M
	Total Assets
22.05M	1.47M	4.97M	14.76M	28.23M	18.68M
	Total Debt
124.21K	328.53K	322.51K	624.53K	797.21K	898.92K
	Net Debt
-20.08M	-536.31K	-3.16M	-10.80M	-26.47M	-16.74M
	Total Liabilities
1.17M	1.68M	1.80M	1.75M	1.74M	1.84M
	Stockholders Equity
20.88M	-211.88K	3.17M	13.01M	26.49M	16.84M
Cash Flow		Free Cash Flow
-7.68M	-8.60M	-7.29M	-15.36M	-13.51M	-16.95M
	Operating Cash Flow
-7.68M	-8.60M	-7.29M	-15.23M	-13.47M	-16.95M
	Investing Cash Flow
-1000.00K	0.00	-936.28K	-115.52K	-43.88K	0.00
	Financing Cash Flow
6.06M	5.98M	283.88K	-494.92K	23.14M	16.32M

Oragenics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OGEN, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.24, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.21 is Neutral, neither overbought nor oversold. The STOCH value of 50.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OGEN.

Oragenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.33	-39.82%	2.92%	17.95%	1.84%
XBIO	43 Neutral	$3.73M	―	-50.12%	―	-1.56%	5.01%
TOVX	41 Neutral	$3.89M	―	-87.31%	―	―	6.87%
JAGX	41 Neutral	$4.11M	―	-522.60%	―	19.75%	95.65%
KZIA	31 Underperform	$3.85M	―	-2639.52%	―	―	19.58%
OGEN	29 Underperform	$4.02M	―	-714.95%	―	-100.00%	76.55%

Oragenics Corporate Events

Oragenics Announces Leadership Changes and Relocation

On January 16, 2025, Oragenics, Inc.’s Board of Directors appointed Ms. Janet Huffman as the Interim Chief Executive Officer, effective immediately. This appointment came with modifications to her employment agreement, including a salary increase to $275,000 and a change in her working location to Sarasota, following the company’s relocation from Tampa. Additionally, she received a discretionary cash bonus of $75,000. On January 15, 2025, Mr. Bruce Cassidy resigned as director to pursue other opportunities, with his resignation unrelated to any disagreements with the company.